Negative CD19 expression is associated with inferior relapse‐free survival in children with RUNX1‐RUNX1T1–positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML‐05 study

Summary We performed a retrospective analysis of leukaemic surface antigen expression and genomic data from a total of 100 RUNX1‐RUNX1T1–positive paediatric acute myeloid leukaemia (AML) patients enrolled in the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) AML‐05 protocol to determine...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2019-11, Vol.187 (3), p.372-376
Main Authors: Sakamoto, Kenichi, Shiba, Norio, Deguchi, Takao, Kiyokawa, Nobutaka, Hashii, Yoshiko, Moriya‐Saito, Akiko, Tomizawa, Daisuke, Taga, Takashi, Adachi, Soichi, Horibe, Keizo, Imamura, Toshihiko
Format: Article
Language:English
Subjects:
acute myeloid leukaemia
Acute myeloid leukemia
CD19
CD19 antigen
Hematology
Leukemia
Lymphoma
Multivariate analysis
Risk factors
Runx1 protein
RUNX1‐RUNX1T1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary We performed a retrospective analysis of leukaemic surface antigen expression and genomic data from a total of 100 RUNX1‐RUNX1T1–positive paediatric acute myeloid leukaemia (AML) patients enrolled in the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) AML‐05 protocol to determine risk factors for relapse. In univariate analysis, the KIT exon 17 mutation (n = 21) and CD19 negativity (n = 59) were significant risk factors for relapse (P = 0·01). In multivariate analysis, CD19 negativity was the sole significant risk factor for relapse (hazard ratio, 3·09; 95% confidence interval, 1·26–7·59; P 
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16080